Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G7MV
|
|||
| Former ID |
DCL000544
|
|||
| Drug Name |
INCB24360
|
|||
| Synonyms |
Epacadostat
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Urothelial carcinoma [ICD-11: 2C92.0] | Phase 3 | [1] | |
| Melanoma [ICD-11: 2C30; ICD-9: 172] | Phase 2 | [2], [3], [4] | ||
| Solid tumour/cancer [ICD-11: 2A00-2F9Z; ICD-10: C76-C80; ICD-9: 140-229] | Phase 2 | [5], [6] | ||
| B-cell lymphoma [ICD-11: 2A86; ICD-10: C85.1; ICD-9: 202.8] | Phase 1 | [2] | ||
| Colorectal cancer [ICD-11: 2B91.Z] | Phase 1 | [2] | ||
| Head and neck cancer [ICD-11: 2D42] | Phase 1 | [2] | ||
| Lung cancer [ICD-11: 2C25.0; ICD-9: 162] | Phase 1 | [2] | ||
| Lymphoma [ICD-11: 2A80-2A86; ICD-9: 202.8, 208.9] | Phase 1 | [2] | ||
| Merkel cell carcinoma [ICD-11: 2C34; ICD-10: C44] | Phase 1 | [2], [3] | ||
| Ovarian cancer [ICD-11: 2C73; ICD-10: C56; ICD-9: 183] | Phase 1 | [2] | ||
| Recurrent glioblastoma [ICD-11: 2A00.00; ICD-10: C71] | Phase 1 | [7], [2] | ||
| Company |
Incyte
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C11H13BrFN7O4S
|
|||
| Canonical SMILES |
C1=CC(=C(C=C1N=C(C2=NON=C2NCCNS(=O)(=O)N)NO)Br)F
|
|||
| InChI |
1S/C11H13BrFN7O4S/c12-7-5-6(1-2-8(7)13)17-11(18-21)9-10(20-24-19-9)15-3-4-16-25(14,22)23/h1-2,5,16,21H,3-4H2,(H,15,20)(H,17,18)(H2,14,22,23)
|
|||
| InChIKey |
FBKMWOJEPMPVTQ-UHFFFAOYSA-N
|
|||
| CAS Number |
CAS 1204669-58-8
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Interaction between the Drug and Microbe | Top | |||
|---|---|---|---|---|
| The Metabolism of Drug Affected by Studied Microbe(s) | ||||
| The Order in the Taxonomic Hierarchy of the following Microbe(s): Gut microbiota | ||||
| Studied Microbe: Gut microbiota unspecific | [8] | |||
| Resulting Metabolite | M11 | |||
| Metabolic Effect | Decrease activity | |||
| Description | Epacadostat can be metabolized to M11 by gut microbiota, which results in the decrease of the drug's activity. | |||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Indoleamine 2,3-dioxygenase 1 (IDO1) | Target Info | Inhibitor | [9] |
| BioCyc | Superpathway of tryptophan utilization | |||
| Tryptophan degradation | ||||
| L-kynurenine degradation | ||||
| Tryptophan degradation to 2-amino-3-carboxymuconate semialdehyde | ||||
| NAD de novo biosynthesis | ||||
| KEGG Pathway | Tryptophan metabolism | |||
| Metabolic pathways | ||||
| African trypanosomiasis | ||||
| NetPath Pathway | TSLP Signaling Pathway | |||
| IL5 Signaling Pathway | ||||
| TGF_beta_Receptor Signaling Pathway | ||||
| Pathwhiz Pathway | Tryptophan Metabolism | |||
| Reactome | Tryptophan catabolism | |||
| WikiPathways | Tryptophan metabolism | |||
| Metabolism of amino acids and derivatives | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03361865) Pembrolizumab in Combination With Epacadostat or Placebo in Cisplatin-ineligible Urothelial Carcinoma (KEYNOTE-672/ECHO-307). U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 3 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 4 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 5 | URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 8221). | |||
| REF 6 | ClinicalTrials.gov (NCT01961115) INCB024360 and Vaccine Therapy in Treating Patients With Stage III-IV Melanoma. U.S. National Institutes of Health. | |||
| REF 7 | Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA) | |||
| REF 8 | Gut microbiota modulates drug pharmacokinetics. Drug Metab Rev. 2018 Aug;50(3):357-368. | |||
| REF 9 | Incyte. Product Development Pipeline. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.